Spots Global Cancer Trial Database for esophageal squamous cell cancer
Every month we try and update this database with for esophageal squamous cell cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining | NCT03180944 | Mucosal Irritat... Image Quality | 1.2% Lugol's so... 1.0% Lugol's so... 0.8% Lugol's so... 0.6% Lugol's so... 0.4% Lugol's so... | 40 Years - 74 Years | Shandong University | |
| Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. | NCT01993784 | Esophageal Squa... | nimotuzumab | 18 Years - 75 Years | Peking University | |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | NCT01351103 | Pancreatic Canc... BRAF Mutant Col... Melanoma Triple Negative... Head and Neck S... Cervical Squamo... Esophageal Squa... Lung Squamous C... | LGK974 PDR001 | 18 Years - | Novartis | |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | NCT05945823 | Locally Advance... Esophageal Aden... Esophageal Squa... Siewert Type 1 ... Pancreatic Canc... | Futibatinib Pembrolizumab Cisplatin 5-FU Oxaliplatin Leucovorin Levoleucovorin Irinotecan | 18 Years - | Taiho Oncology, Inc. | |
| Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining | NCT03180944 | Mucosal Irritat... Image Quality | 1.2% Lugol's so... 1.0% Lugol's so... 0.8% Lugol's so... 0.6% Lugol's so... 0.4% Lugol's so... | 40 Years - 74 Years | Shandong University | |
| Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | NCT01336049 | Esophageal Squa... | Nimotuzumab | 18 Years - 75 Years | Peking University | |
| Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | NCT01336049 | Esophageal Squa... | Nimotuzumab | 18 Years - 75 Years | Peking University | |
| Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer | NCT01627379 | Esophageal Squa... | Cisplatin, 5-FU Panitumumab | 18 Years - | AIO-Studien-gGmbH | |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | NCT01351103 | Pancreatic Canc... BRAF Mutant Col... Melanoma Triple Negative... Head and Neck S... Cervical Squamo... Esophageal Squa... Lung Squamous C... | LGK974 PDR001 | 18 Years - | Novartis | |
| Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy | NCT03223662 | Esophageal Canc... Esophageal Aden... Esophageal Squa... Esophageal Neop... Squamous Cell C... | Chemoradiothera... Esophagectomy | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
